Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 11 - 04 symbols : Igms save search
Multimeric IgM Antibodies Targeting DR5 are Potent and Rapid Inducers of Tumor Cell Apoptosis In Vitro and In Vivo
Published: 2021-11-04 (Crawled : 17:00) - igmbio.com
IGMS | News | $7.4 -8.98% -9.86% 450K
|
Health Technology
|
| O: -9.65%
H: 10.43%
C: 8.35%
antibody in vitro
Birinapant clinical study initiated by IGM Biosciences
Published: 2021-11-04 (Crawled : 14:15) - prnewswire.com
IGMS | News | $7.4 -8.98% -9.86% 450K
|
Health Technology
|
| O: -9.65%
H: 10.43%
C: 8.35%
initiated bioscience
Abstract #132: A Phase 1 Dose Escalation Study of IGM-2323, a Novel Anti-CD20 x Anti-CD3 IgM T Cell Engager (TCE) in Patients with Advanced B-Cell Malignancies
Published: 2021-11-04 (Crawled : 14:00) - igmbio.com
IGMS | News | $7.4 -8.98% -9.86% 450K
|
Health Technology
|
| O: -9.65%
H: 10.43%
C: 8.35%
anti-cd3 phase 1 t-cell
IGM Biosciences Announces Third Quarter 2021 Financial Results and Provides Corporate Update
Published: 2021-11-04 (Crawled : 14:00) - igmbio.com
IGMS | News | $7.4 -8.98% -9.86% 450K
|
Health Technology
|
| O: -9.65%
H: 10.43%
C: 8.35%
financial results results bioscience
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.